Literature DB >> 6237158

The intracutaneous growth of murine lymphomas: epidermal invasion is characteristic of multiple tumor phenotypes.

M Piepkorn, R E Tigelaar.   

Abstract

Affinity of lymphoid cells for the epidermis (epidermotropism) is characteristic of the cutaneous T-cell lymphomas, mycosis fungoides and the Sézary syndrome. Consistent with numerous studies indicating that mycosis fungoides is a neoplasm of OKT4+T8- ("helper/inducer") T lymphocytes is the possibility that epidermotropism is a phenotypic hallmark of this subset of malignant T cells. This proposal was investigated in mice using 8 phenotypically characterized lymphomas of BALB/c origin: 3 histiocytic (phagocytic, lysozyme-positive, FcR+, Ig-, Thy 1-), 1 B-cell (IgM+, FcR+, Thy 1-), and 4 T-cell (Ig-, Thy 1+) lines, including 1 with markers of mouse helper/inducer T cells (Lyt1+23-), 2 with suppressor/cytotoxic markers (Lyt1-23+), and 1 with markers of immature thymocytes (Lyt1+23+). The intracutaneous growth pattern of these lines was studied on hematoxylin and eosin-stained sections through the centers of tumors obtained at times after intradermal injection into parallel groups of syngeneic mice. All of these lymphomas manifested variable epidermotropism that followed a typical sequence. Following dermal growth and spread to the dermal-epidermal junction, tumor cells appeared within the stratum spinosum. Subsequently, collections of cells appeared in spaces within the epidermis (Pautrier-like microabscesses) in tumors greater than 2 cm in diameter, coincident with early epidermal necrosis. Thus, in this animal model it is clear that the intraepidermal invasion/growth does not correlate with the helper/inducer T-cell surface phenotype. These observations are nonetheless consistent with recent studies using monoclonal antibodies to cell surface antigens which have demonstrated a heterogeneity of lymphoid cell subsets within the epidermis in lesions of mycosis fungoides and of other malignant and benign dermatoses.

Entities:  

Mesh:

Year:  1984        PMID: 6237158     DOI: 10.1111/1523-1747.ep12340368

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Small, freshly arrived histiocytes in cutaneous and mucosal herpetic lesions.

Authors:  J J van den Oord; R De Vos; C De Wolf-Peeters
Journal:  Arch Dermatol Res       Date:  1996-08       Impact factor: 3.017

2.  Cutaneous B-cell lymphoma in a Perdido Key Beach mouse (Peromyscus poliontus trissyllepsis).

Authors:  Copper Aitken-Palmer; Matti Kiupel; Kathy Russell; Linda Hayes; Darryl Heard
Journal:  Comp Med       Date:  2012-04       Impact factor: 0.982

3.  Simultaneous integrated boost with helical arc radiotherapy of total skin (HEARTS) to treat cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia - dosimetry comparison of different regimens and clinical application.

Authors:  Chen-Hsi Hsieh; Hui-Ju Tien; Yuan-Bin Yu; Yuan-Hung Wu; Pei-Wei Shueng; Yueh-Feng Lu; Shan-Ying Wang; Li-Ying Wang
Journal:  Radiat Oncol       Date:  2019-01-28       Impact factor: 3.481

Review 4.  Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.

Authors:  Raman Preet Kaur Gill; Jennifer Gantchev; Amelia Martínez Villarreal; Brandon Ramchatesingh; Elena Netchiporouk; Oleg E Akilov; Niels Ødum; Robert Gniadecki; Sergei B Koralov; Ivan V Litvinov
Journal:  Cells       Date:  2022-02-09       Impact factor: 6.600

5.  Sézary syndrome patient-derived models allow drug selection for personalized therapy.

Authors:  Fernando Gallardo; Evelyn Andrades; Arnau Iglesias; Jessica González; Laura Solé; Yolanda Guillén; Gonzalo Blanco; Luis Colomo; Eva Gimeno; David Conde; Eva Rodriguez; Isabel Bielsa-Marso; Mar Iglesias; Beatriz Bellosillo; Ramon M Pujol; José R Regueiro; Anna Bigas; Lluís Espinosa
Journal:  Blood Adv       Date:  2022-06-14

6.  Epidermotropic marginal zone lymphoma: An uncommon cutaneous B-cell lymphoma responsive to rituximab.

Authors:  Cynthia M Magro; Tracy L Davis; Drew J B Kurtzman
Journal:  JAAD Case Rep       Date:  2017-09-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.